Author pages are created from data sourced from our academic publisher partnerships and public sources.
Integrative Clinical Genomics of Advanced Prostate Cancer
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct… Expand
Enzalutamide in metastatic prostate cancer before chemotherapy.
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after… Expand
Abiraterone in metastatic prostate cancer without previous chemotherapy.
BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this… Expand
OncoKB: A Precision Oncology Knowledge Base.
PURPOSE With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for a clinical support tool that distills the clinical implications associated… Expand
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate cancer has hampered progress in understanding disease pathogenesis and therapy response. Using a 3D… Expand
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
- J. Carrasquillo, J. O'Donoghue, +9 authors M. J. Morris
- European Journal of Nuclear Medicine and…
- 8 May 2013
Purpose223Ra-Dichloride (223Ra) is a novel bone-seeking alpha-emitter that prolongs survival in patients with castration-resistant metastatic prostate cancer. We conducted a study to better profile… Expand
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
AbstractPersistent androgen receptor (AR) signaling despite low levels of serum androgens has been identified as a critical target for drug discovery in castration-resistant prostate cancer (CRPC).… Expand
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
- D. Rathkopf, M. Morris, +11 authors H. Scher
- Journal of clinical oncology : official journal…
- 3 September 2013
PURPOSE ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen… Expand
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Background Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene… Expand
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
PurposeHistone deacetylase inhibitors have demonstrated anticancer activity against a range of tumors. We aimed to define the maximum tolerated dose, toxicity, activity, and pharmacokinetics of oral… Expand